The headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically ...

AstraZeneca has confirmed that some of its current and former employees have been taken into custody in China as part of an ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), ...

The agreement ties in with Lilly's strategy of making genetic medicines targeting DNA and RNA a key pillar of its R&D, ...

The company recently claimed FDA approval for the first description DTx for major depressive disorder (MDD) – ...

The CEO's departure comes after Lykos co-founder and longtime psychedelic medicines advocate Rick Doblin stood down from the ...

Pay a tax of up to 1,900% (not 95%) on the total sales revenue of the medicine selected for price setting. News coverage ...

There is broad recognition of the need to promote diversity and inclusion in clinical trials, with the goal of improving ...

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies ...

Emergent BioSolutions, which is one of only three companies with a vaccine for mpox, has agreed to donate 50,000 doses of ...

J&J has taken all its talc-based products off the market as of 2023 and is now using cornstarch instead. In its ...

Vaxcyte said its vaccine covers serotypes involved in around 95% of invasive pneumonia disease (IPD) cases in the US. It ...